Predictive molecular signature in lymphoma may direct targeted therapy
Press Release: Dana-Farber Cancer Institute September 10, 2012 Researchers from Dana-Farber Cancer Institute, the Broad Institute, Boston University and colleagues have found a molecular “signature” in a common form of lymphoma that identifies patients unlikely to respond to standard chemotherapy, and who might benefit instead from treatment with certain experimental targeted drugs. The discovery came from […]
Developing tools for early detection of lung cancer
We are leading a $13.6 million study aimed at developing novel technologies for the early detection of lung cancer. The five-year multi-site, multi-phase study that will focus on active military personnel and veterans is funded by the United States Department of Defense (DOD) Lung Cancer Research Program. We are collaborating with military hospitals and Veteran’s Affairs […]
Identifying smokers who are at high risk for developing lung cancer
Although only a subset of smokers develop lung cancer, we cannot determine which smokers are at highest risk for cancer development, nor do we know the signaling pathways altered early in the process of tumorigenesis in these individuals. On the basis of the concept that cigarette smoke creates a molecular field of injury throughout the respiratory tract, this […]